No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Conclusions: For the H/VH risk group, very poor cytogenetic risk, age ≥ 65 years, ECOG PS 2 to 4, and AML transformation were poor prognostic factors. HMA showed no benefit in terms of OS when compared to BSC. Allo-HCT was the only factor predicting a favorable long-term outcome. The use of HMA therapy did not seem to have an adverse effect on the transplantation outcomes. However, the conclusion of this study should be carefully interpreted and proven by large scale research in the future.
PMID: 29232940 [PubMed - as supplied by publisher]
Source: The Korean Journal of Internal Medicine - Category: Internal Medicine Authors: Sohn SK, Moon JH, Lee IH, Ahn JS, Kim HJ, Chung JS, Shin HJ, Park SW, Lee WS, Lee SM, Kim H, Lee HS, Kim YS, Cho YY, Bae SH, Lee JH, Kim SH, Song IC, Kwon JH, Lee YJ Tags: Korean J Intern Med Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Databases & Libraries | Internal Medicine | Leukemia | Myelodysplastic Syndrome | Study | Transplants